Article Information
History
- August 29, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- N. Ahmad Aziz, MD, PhD1,2,
- Victor M. Corman, MD, PhD3,
- Antje K.C. Echterhoff, PhD1,
- Anja Richter3,
- Antonio Schmandke, PhD1,
- Marie Luisa Schmidt3,
- Thomas H. Schmidt, PhD1,
- Folgerdiena M. de Vries, PhD1,
- Christian Drosten, MD, PhD3 and
- Monique M.B. Breteler, MD, PhD1,4,*
- 1Population Health Sciences, German Center for Neurodegenerative diseases (DZNE), Bonn, Germany
- 2Department of Neurology, Faculty of Medicine, University of Bonn, Bonn, Germany
- 3National Consultant Laboratory for Coronaviruses, Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 4Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Germany
- ↵*
Corresponding author:
Prof. Dr. Monique M.B. Breteler, MD, PhD Population Health Sciences, German Center for Neurodegenerative diseases (DZNE) within the Helmholtz Association Venusberg-Campus 1, Building 99 53127 Bonn, Germany, Tel: +49-228-43302-929, E-mail: monique.breteler{at}dzne.de
Posted August 29, 2020.
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
